The 9th International Conference on Emerging Technologies in Drug Discovery and Development (IAPC-9) will be organized by the International Association of Physical Chemists, ADMET and DMPK Journal and co-organized by Shanghai Hengrui Pharmaceutical Co., Ltd. The conference is aimed at providing a unique global forum where scientists working in different but closely related areas of pharmaceutical research, from drug discovery through to drug development, will meet in a relaxed atmosphere to discuss and rationalize their results and challenges.

    Co-organized by:   

IAPC logo4

Hengrui bez


Read more....

Scientific program
Social events
Abstract submission
SCI journal publication
Other publishing options
Registration options
How to register
Key dates

Featured speakers

Klara Valko
Klara obtained her PhD at Semmerlweis University in Budapest. Since 1995 Klara has been working with the Physico-chemical Characterization Group at GSK. Now she is director of Bio-Mimetic Chromatography Consultancy providing data analysis, biomimetic HPLC method set up and measurements, in vivo drug distribution modelling and various courses to pharmaceutical companies and manufacturers of analytical equipment. Klara is also a honorary professor at University College London, where she has been teaching the Physchem/ADME module for the Drug Discovery. She has published over 100 papers that achieved over 3000 citations. She wrote a book on “Physicochemical and Biomimetic Properties in Drug Discovery; Chromatographic Techniques for lead optimization” published by Wiley in 2014.

Klara ValkoBiomimetic chromatography

Duanyun Si
Dr. Duanyun Si joined Tianjin Institute of Pharmaceutical Research (Tianjin, China) in 2005. as a PI and professor for new drug/formulation ADME assessment to support the drug/formulation development process across China and beyond. In 2009, He became Executive Director in State Key Laboratory of Drug Delivery Technology and Pharmacokinetics. Starting from Oct. 2018, Dr. Si acts as the President in the Professional Committee of Studying Xenobiotics, Chinese Pharmacological Society. Dr. Si's research interests are focused on drug metabolism, drug disposition, bioanalysis, and organic mass spectrometry to support new drug/formulation and generic drug ADME/BE assessments during R&D phases of IND, NDA and ANDA.

Duanyun SiDirector of State Key Laboratory, Tianjin

Johan Gabrielsson
Professor of integrative pharmacology +20 years of industrial experience as Senior Principal Scientist in research areas such as CV & GI & CNS & Cancer & Biologics. Author of the textbooks 'Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications' 5th ed. (2016) and 'Quantitative Pharmacology: An Introduction to Integrative Pharmacokinetic-Phar­macodynamic Analysis' 1st ed. (2012).

Johan GabrielssonProf. of integrative pharmacology

Christel Bergström
Dr Bergström is Associate Professor in Pharmaceutics at Uppsala University where she is heading a research group focusing on delivery of poorly soluble compounds. She is in the steering committee of the Swedish Drug Delivery Forum where she also leads the Oral Drug Delivery Platform with drug delivery to the colon and intestinal absorption of biologics being in focus. Dr Bergström is the cofounder of Center of Pharmaceutical Informatics at Uppsala University (now UDOPP) She is a cofounder of the Nordic Pharma Network and an EXCO member of a recently awarded NordForsk grant for a Nordic University Hub within patient-oriented products. She is also an EXCO member of the Globalization Pharmaceutics Education Network. In 2017, she was elected Deputy Dean of collaboration (Medicine and Pharmacy) at Uppsala University.

Christel BergströmUppsala University

Alex Avdeef
Alex Avdeef, PhD, is an AAPS Fellow, and the author of Absorption and Drug Development, Wiley, 2012. For over 40 years, he has been teaching, researching, & developing methods, instruments, & analysis software for measurement of ionization constants, solubility of practically-insoluble drugs, miniaturized dissolution, & permeability. His accomplishments in the development of instrumentation include several well-known instruments currently manufactured by leading companies in the instrument market (e.g., ORION960 Autochemistry System). He has over 120 technical publications in primary scientific journals & chapters in books, 6 patents. He founded in-ADME Research (USA) and co-founded pION INC (USA) in 1996 & Sirius Analytical (UK) in 1989.

Alex AvdeefCEO, in-ADME Research

Dafang Zhong
Dr. Zhong obtained his Ph.D. (1989) degree in Pharmaceutical Chemistry from the University of Bonn, Germany. From 1994-2005, he worked as a professor in Shenyang Pharmaceutical University. Since June 2005, he has led the Center for DMPK Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has published more than 400 papers He is a member of Chinese Pharmacopeia Commission and drafted the Guidance for Bioavailability and Bioequivalence Studies for Drug Preparations as well as Guidelines for Bioanalytical Method Validation for Chinese Pharmacopeia 2015. He also severs as an editor for Biomedical Chromatography, Journal of Chromatography B, and Bioanalysis.

Dafang ZhongProfessor and PI

Wouter Driessen
As a project leader at Roche, Wouter is responsible for the early implementation of integrated, preclinical DMPK/PD strategies across various therapeutic modalities (small molecules, novel antibody constructs, oligonucleotides, and cell therapies), with a focus on (onco-)immunology and inflammation. Wouter received his Ph.D. in pharmaceutics at the University of Florida. He joined iThera Medical that is driving the field of optoacoustic imaging, both for preclinical and clinical use. In 2014, Wouter joined F. Hoffmann-La Roche as a DMPK/PD project leader.

Wouter DriessenPrincipal scientist, Roche, Shanghai

Weikang Tao
Dr. Weikang Tao has served as corp vice president of Jiangsu Hengrui Medicine Co., Ltd. and the CEO of R&D Centers since Feb. 2014. In this position, he has led the R&D Centers consisting of about 500 scientists and located in China and in the US to discover and develop innovative medicines, ranging from small molecule drugs, therapeutic antibodies and peptides, antibody-drug conjugates and cellular therapies in multiple therapeutic areas.Dr. Tao has published more than 40 peer-reviewed research papers in premier life science journals and he is the holder of many issued and pending patents in drug discovery. He obtained a Ph.D. degree in Molecular & Cell Biology from the University of Medicine & Dentistry of New Jersey in the US. He was a post-doctoral fellow in Prof. Arnold Levine’s Lab at Princeton University.

Weikang TaoCEO, Hengrui R&D


Emerging technologies in drug discovery and developments is annual conference taking place in alternate European/Eastern Asia regions

Learn more


One or two-day intensive courses designed for students and pharmaceutical researchers who wish to broaden their knowledge and advance in the career.

More details

Social events

Rich social events will provide relaxed atmosphere for getting togehter

More Details